Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufacture...

FDA Recall #D-0006-2026 — Class II — September 16, 2025

Recall #D-0006-2026 Date: September 16, 2025 Classification: Class II Status: Ongoing

Product Description

Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.

Reason for Recall

Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

Recalling Firm

ACCORD HEALTHCARE, INC. — Raleigh, NC

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

54,432 bottles

Distribution

Nationwide in the US

Code Information

Lot # D2300045, Exp 12/31/2025.

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated